All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Brimonidine Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Lumify
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
Results of new investigational in vitro data shows that two benzalkonium chloride preserved eye drops, LUMIFY® redness reliever eye drops and BESIVANCE® 0.6%, indicated complete inactivation of Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2 or COVID-19).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CB5138 Analog peptides,Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
Preclinical data shows that combination of a CB5138 Analog with nintedanib, the leading standard of care for treatment of Idiopathic Pulmonary Fibrosis (IPF), produced enhanced effects compared to nintedanib alone in mice.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cymerus mesenchymal stem cells
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
Treatment with Cynata’s Cymerus MSCs led to statistically significant improvements in multiple harmful effects of IPF, including interstitial fibrosis, dynamic lung compliance and airway resistance.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Recombinant human plasma gelsolin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2020
Details:
The compelling data from this NIH sponsored study show the potential of gelsolin to not only improve survival, but to diminish lung injury caused by virulent pneumonia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Exebacase
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CF-370
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Cystic Fibrosis Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding August 25, 2020
Details:
First stage of the agreement will fund in vitro activity of ContraFect’s next product candidate, CF-370, an engineered lysin targeting Pseudomonas aeruginosa, and amurin peptides, against bacterial specimens obtained from CF patients at different stages of disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MORF-720
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MORF-720
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $120.0 million Upfront Cash: $100.0 million
Deal Type: Licensing Agreement August 25, 2020
Details:
AbbVie has exercised a license option under the companies’ research and development collaboration agreement to develop Morphic’s αvβ6 integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ASX-100
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ASX-100
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Orange Grove Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding August 25, 2020
Details:
ASX-100 is a novel, spherical polymer particle that degrades into salicylic acid – an active metabolite of aspirin – and a food additive that is listed as GRAS (generally regards as safe) by the FDA. Seed funding will be used in first-in-human trials of the drug.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NXP004
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NXP004
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2020
Details:
NXP004 showed a dose-dependent reduction in the secretion of several key ECM components.These data suggest NXP004 compares favourably to current standard of care with regard to anti-fibrotic activity in this model.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RXC006
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RXC006
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: $377.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 04, 2020
Details:
Under the terms of the exclusive global agreement, AstraZeneca will take RXC006 forward into clinical development, targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OB-002
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: OB-002
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: National Research Council Industrial Research Assistance Program
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding July 30, 2020
Details:
Funding from the National Research Council Industrial Research Assistance Program will support the development of Orion’s lead compound, OB-002, a promising treatment for SARS-CoV-2 infection associated acute respiratory distress syndrome (ARDS).
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
